Less Ads, More Data, More Tools Register for FREE

Cyprus suspends AstraZeneca vaccine pending EU agency review

Mon, 15th Mar 2021 20:15

NICOSIA, March 15 (Reuters) - Cyprus suspended AstraZeneca
shots for COVID-19 on Monday pending a review by the European
Medicines Agency (EMA), its health ministry said.

The suspension, which followed a similar move on Monday by
Germany, France and Italy, will last until March 18, when the
EMA is due to issue a review of the vaccine following reports of
thrombosis among some recipients in Europe, the ministry said.

The World Health Organization (WHO) has said there is no
proven link and that people should not panic.

Cyprus' inoculation programme with vaccines from
Pfizer/BioNtech and Moderna will continue, the health ministry
said. There have been no publicly reported cases of any side
effects from the AstraZeneca vaccine in Cyprus.

Norway and Denmark stopped giving AstraZeneca shots last
week after reporting isolated cases of bleeding, blood clots and
a low platelet count. Iceland and Bulgaria followed suit and
Ireland and the Netherlands announced suspensions on Sunday.

Spain will stop administering the vaccine for at least 15
days, Cadena Ser radio reported, citing unnamed sources.

The top WHO scientist reiterated on Monday that there have
been no documented deaths linked to any COVID-19 vaccines.
(Writing By Michele Kambas
Editing by Gareth Jones)

Related Shares

More News
Today 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Today 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an ora...

28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant sa...

27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.